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The clinical applications of magnetic hyperthermia therapy (MHT) have been largely hin-
dered by the poor magnetic-to-thermal conversion efficiency of MHT agents. Herein, we
develop a facile and efficient strategy for engineering encapsulin-produced magnetic iron
oxide nanocomposites (eMIONs) via a green biomineralization procedure. We demonstrate
that eMIONs have excellent magnetic saturation and remnant magnetization properties,
featuring superior magnetic-to-thermal conversion efficiency with an ultrahigh specific
absorption rate of 2390W/g to overcome the critical issues of MHT. We also show that
eMIONs act as a nanozyme and have enhanced catalase-like activity in the presence of an
alternative magnetic field, leading to tumor angiogenesis inhibition with a corresponding
sharp decrease in the expression of HIF-1α. The inherent excellent magnetic-heat capability,
coupled with catalysis-triggered tumor suppression, allows eMIONs to provide an MRI-
guided magneto-catalytic combination therapy, which may open up a new avenue for bench-
to-bed translational research of MHT.
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Magnetic hyperthermia therapy (MHT) is a newapproach for minimally invasive treatment of cancer1,2and has been tested in the clinic3–5. Among the various
types of magnetic thermal induction agents, iron oxide nano-
particles (IONs) show some promise due to their safety and
magnetic property (e.g., clinical contrast agents for magnetic
resonance imaging (MRI))6–8. However, conventional super-
paramagnetic IONs suffer from low magnetic-to-thermal con-
version efficiency9–12, and the highest reported specific
absorption rate (SAR) of superparamagnetic IONs is only 487W/
g4, which is insufficient for effective MHT in the range of safe
dosage in clinical application. Another issue is the poor stability
of ferrimagnetic materials in the presence of an alternative
magnetic field (AMF), which are less favorable for biomedical
applications in spite of their relatively high heat-induction effi-
ciency3. Therefore, it is imperative to develop IONs with opti-
mized magnetic-to-thermal conversion efficiency and great
biocompatibility for the clinical translation of MHT.
Recently, bionics technology such as biomineralization has
drawn much attention to produce uniform, stable, and well-
ordered IONs via precise control of ion concentration, nucleation
process, pH, or redox potential in magnetic protein nanocages13.
Various magnetic protein nanocages with ferroxidase centers
(FOCs), functional proteins to facilitate mineralization, exist in
bacteria, ranging from small DNA-binding protein from starved
cells (Dps) cage (8 nm), mid-sized ferritin (12 nm), to the large
virus capsid-like encapsulins (24 nm or 32 nm)14–19, but no
efforts have been reported to investigate whether magnetic pro-
tein nanocages can be used as MHT agents. Interestingly, these
protein nanocages offer a highly tunable environment and facile
control of the composition, morphology, magneto-crystalline
anisotropy, and magnetization of IONs. Therefore, we hypothe-
size that IONs derived from magneto-protein nanocages with
improved heating efficiency may be able to overcome the current
obstacles of MHT.
Encapsulin is an iron-storage protein nanocage in Myxococous
xanthus, featuring excellent biocompatibility, the appropriate size
of the cavity, and FOCs16. In this study, we genetically engineered
encapsulin protein nanocages to produce high-quality IONs via a
biomineralization procedure (Fig. 1a). The encapsulin-produced
magnetic IONs (eMIONs) consist of FeO subdomains containing
Fe3O4 with ~100% crystallinity. Notably, eMIONs have excellent
magnetic saturation and remnant magnetization to produce
coercive force under AMF, which significantly improves the
energy-dissipation rate to promote the magnetic-to-thermal
conversion capacity20,21, achieving an ultrahigh SAR of 2390
W/g in AMF at 300 kHz and 15 kA/m. Moreover, eMIONs are
excellent intrinsic catalase-like nanozymes and show enhanced
catalytic activity in the presence of AMF to achieve synergy effects
for MHT. The MRI-guided magneto-catalytic combination
therapy (MCT) shows great tumor suppression and nearly dou-
bled survival time of orthotopic hepatocellular carcinoma (HCC)-
bearing mice. Therefore, eMIONs have great potential to be a
clinically translatable MHT agent to overcome the crucial issues
facing MHT (Fig. 1b).
Results
Engineering and characterization of encapsulin protein
nanocage. The recombinant encapsulin protein nanocage
(encABC) was genetically engineered as follows: the shell protein
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Fig. 1 Schematic illustration of magneto-catalytic theranostics. a Schematic of an encABC and its biomimetic mineralized procedure. The inner cores of
encapsulin-produced magnetic iron oxide nanocomposites (eMIONs) have the optimal size for magnetic hyperthermia induction and consist of FeO
subdomain-containing Fe3O4, with ~100% crystallinity, and have remnant magnetization, thus achieving prominent magnetic-heat induction in an
alternative magnetic field (AMF). Moreover, eMIONs are great catalase-like nanozymes that can be utilized for catalytic therapy. b eMIONs accumulated
in tumor sites and suppressed tumor growth effectively, as monitored by multimodality imaging. eMIONs retained in the tumor region augmented oxygen
production to modulate the tumor microenvironment, decrease HIF-1α, and VEGF expression. Then, at an optimal time point, AMF not only induced MHT
but also improved the catalytic efficacy, resulting in a magneto-catalytic therapy (MCT).
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encA was cloned into an expression cassette of pRSFDuet-1
plasmid, the inner functional proteins encB and encC were cloned
into different expression cassettes of pCDFDuet-1 simultaneously
(Supplementary Fig. 1a), and then the plasmids were co-
transformed into E. coli BL 21 to obtain encABC. Cryo-electron
microscopy (cryo-EM, Supplementary Fig. 1b) and transmission
electron microscopy (TEM) confirmed that the purified material
was composed of a homogeneous spherical particle about 32 nm
in diameter (Fig. 2a). The recovered structure of encABC (Fig. 2b,
c) showed the same structure as the native nanocompartment,
featuring a hollow icosahedral symmetry structure made of 180
encA subunits with holes ~3 Å in diameter on its surface.
Moreover, SDS-PAGE (Supplementary Fig. 1c) demonstrated that
the particles are composed of three proteins: encA (35 kDa), encB
(17 kDa), and encC (13 kDa). Gel quantitation estimated that the
shell protein encA accounts for ~55% of the total protein content,
and the inner function proteins encB and encC account for ~24%
and ~21%, respectively. The expression quantity of functional
proteins encB and encC in the nanocages is about two-fold higher
than that of the native encapsulin16; thus we believed that the
genetically engineered encABC would have much better biomi-
neralization ability.
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Fig. 2 Characterization of encapsulin-produced magnetic iron oxide nanocomposites (eMIONs). a Representative TEM image of encABC (Inset: DLS of
encABC). Scale bar: 100 nm. b, c Isosurface representation of reconstructed nanoparticles color-coded according to the radial distance from the center
(given in Å): b view from the outside; c cutaway view of the internal structure. d Schematic diagram of the biomimetic synthesis of eMIONs and the heat
emission under alternative magnetic field (AMF). e Representative TEM (scale bar: 100 nm) image of eMIONs (inset images I to IV: biomimetic synthesis
time at 0, 1, 3, and 6 h, respectively). Scale bar: 50 nm. f HRTEM and corresponding FFT pattern (inset) of eMIONs nanocrystals, corresponding to {102}-
faceted FeO and {311}-faceted Fe3O4. g XPS analyses of eMIONs. h The results of VSM analysis of eMIONs and fMIONs. i Schematic illustration of
eMIONs and fMIONs for magnetic-to-thermal conversion under AMF. One of three repetitions with similar results is shown here for a, e, and f.
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Biomineralization and characterization of eMIONs for MCT.
The size and crystalline degree of iron cores are essential for ION-
based MHT12. Thus, the mid-sized ferritin magnetic nanocages
were chosen as the control in our experiments. The encABC and
ferritin nanocages were biomineralized to prepare the eMIONs
and ferritin-produced magnetic IONs (fMIONs), respectively
(Fig. 2d). TEM confirmed that purified eMIONs exhibited an
electron-dense core (Fig. 2e and Supplementary Fig. 2a). Addi-
tionally, we found that the diameter of the iron cores of eMIONs
(22 nm) was almost five times larger than that of fMIONs (4.5
nm), as measured by Image J (Supplementary Fig. 2c). TEM
images also revealed that irons could be biomineralized to induce
nucleation in the encABC nanocages, and then grew to form an
iron core via a green biosynthetic procedure (Fig. 2e inset I–IV).
It is also of note that eMIONs have remarkable mineralization
ability, which enables much higher loading of Fe atoms (31,590
atoms/cage) compared with fMIONs (3394 atoms/cage) by
weighing the protein and Fe of the nanocages. Dynamic light-
scattering (DLS) analyses (Supplementary Fig. 2b) showed that
the hydrate particle sizes of eMIONs and fMIONs were 39.3 ± 2.7
nm and 12.6 ± 1.2 nm, respectively. The stability of eMIONs is a
key issue for further biomedical application. Thus, eMIONs were
incubated into various temperature conditions (25, 37, 50, 60, and
70 °C), cell culture with 10% fetal bovine serum (37 °C) and
cathepsin B (0.2 units, 37 °C) solutions for 48 h to investigate the
thermal stability, blood stability, and protease degradation,
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Fig. 3 Functional properties of encapsulin-produced magnetic iron oxide nanocomposites (eMIONs). a Alternative magnetic field (AMF) induced
temperature rise. Data are presented as mean ± SD (n= 5 independent experiments). b Comparison of SAR values of eMIONs to fMIONs and two types of
commercial agents. c T2-weighted MR images and T2 relaxation rates (1/T2, s−1) of eMIONs and fMIONs at different iron concentrations. d Schematic
illustration of eMIONs for enhancing catalysis under AMF. e–g The relative dissolved O2 in H2O2 (100 μM) after incubation of various concentrations of
eMIONs and fMIONs (e, pH 6.8), various pH solutions (f), and various temperatures (g, 1= 25 °C, 2= 37 °C, 3= 43 °C). Data are presented as mean ± SD
(n= 5 independent experiments). Tukey boxplots are shown with the box indicating quartiles and the whiskers drawn at the lowest and highest points
within 1.5 interquartile range of the lower and upper quartiles, respectively. Error bars show the 95% confidence interval for the difference in proportions or
medians between the O2 production. h, i H2O2 (100 μM) decomposition by catalase-like activity of eMIONs with oxygen generation measured by the level
of dissolved oxygen (h) and Michaelis–Menten kinetics (i) of eMIONs/fMIONs with/without AMF.
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respectively. As shown in Supplementary Fig. 2d–f, eMIONs were
monodispersed without obvious aggregation/degradation, exhi-
biting excellent stability in all the conditions.
High-resolution TEM, XPS, and XRD analyses of IONs (Fig. 2f,
g and Supplementary Fig. 3a–d) illustrated that the iron cores of
eMIONs were FeO subdomains containing Fe3O4 (FeO@Fe3O4),
while those of the fMIONs were mainly γ-Fe2O3. XRD data
analyzed through JADE software demonstrated that the degrees
of crystallinity of eMIONs and fMIONs were 99.99% and 47.66%
(Supplementary Fig. 4), respectively. Therefore, we tested the
magnetic field by a vibrating-sample magnetometer (VSM)
(Fig. 2h and Supplementary Fig. 5). The result showed that the
magnetization of eMIONs reached 15.3 emu/g (10 kOe, 300 K),
which is nearly 6.5 times higher than that of commercial IONs
Resovist (2.4 emu/g)22 and 7.5 times higher than that of fMIONs
(2.0 emu/g). Notably, the results also revealed that eMIONs are
multidomain nanoparticles, which have magnetic domains and
remnant magnetization, suggesting that eMIONs could produce
coercive force via hysteresis losses under AMF and significantly
improve the energy-dissipation rate through a potent magnetic to
heat induction19,23,24 (Fig. 2i). These differences between
eMIONs and fMIONs might cause a huge gap in their intrinsic
magnetic and catalytic abilities. Therefore, the heating capacities of
MIONs were measured in AMF with different powers of 10–20 kA/
m at 300 kHz and iron concentrations of 0.1–0.5mM (Fig. 3a and
Supplementary Fig. 6), from which the SAR values were calculated
as well. As expected, eMIONs have an obviously higher SAR value
(2390W/g) as compared to fMIONs (320W/g) and commercial
IONs5, such as Feridex (115W/g) and Resovist (236W/g) (Fig. 3b).
Also, the temperature of eMIONs increased rapidly to reach 42 °C
in 5min with AMF (15 kA/m, 300 kHz), but for fMIONs, it did not
extend beyond 39 °C under the same condition, which is not
surprising since eMIONs have a larger size, higher degree of
crystallinity of iron cores and remnant magnetization to generate
more heat in AMF than fMIONs20. It is also worth noting that the
r2 value of eMIONs was 125mM−1 s−1, whereas the r2 value of
fMIONs was 25.15mM−1 s−1 at 9.4 T (Fig. 3c). In general, higher
r2 values of the IONs correspond with higher suitability of the
contrast agent for T2-weighted imaging, suggesting that eMIONs
have excellent sensitivity for MRI-guided MHT.
The catalase-like ability of eMIONs was investigated to
evaluate its potential for catalytic therapy (Fig. 3d). Initially, the
O2 production abilities of eMIONs and fMIONs were tested at
different concentrations of Fe as well as different pH and
temperature conditions (Fig. 3e–g), which indicated that the
catalysis had an obvious positive correlation with all three
Hsp70
kDa
72 35
19
17
120
150
42
22
14
20
26
kDa
Bid
tBid
Bax
Cyt C
Cas-3
Cl.Cas-3
HIF-1α
VEGF
β-actin
Blank eMIONs
eMIONs
+ AMF Blank eMIONs
eMIONs
+ AMF
eMIONsBlank
Blank eMIONs
eMIONs + AMF
eMIONs + AMF
b
c
a
e
1.5
1.0
0.5
0.0
Hs
p7
0
Bi
d
tB
id
BA
X
Cy
t C
Ca
s-
3
CI
.C
as
-3
HI
F 
1α
VE
GF
d
CFe (μg/mL)
C
el
l v
ia
b
ili
ty
 (
%
)
R
el
at
iv
e 
ex
p
re
ss
io
n
 (
S
/S
0)
P = 0.038
P = 0.006
P = 0.029 P = 0.046
P = 0.004
P = 0.0012
P = 0.0026
P = 0.017
P = 0.02
P = 0.004
P = 0.023
P = 0.017
P = 0.038
100
75
50
25
0
0 5 10 15 20
eMIONs
eMIONs + AMF
2Cat
aly
tic 
the
ra
py
1Magne
tic-therapy
tBid Bid
1
Cyt C
HIF1α
HIF1α
Degradation VEGF
Ca
ta
lys
is
HSP 70
Bax
Cas-3
Apoptosome
Mitochon
dria
O2
H2O2
2
Ac
ce
le
ra
tio
n
Fig. 4 In vitro studies of encapsulin-produced magnetic iron oxide nanocomposites (eMIONs). a Schematic illustration of magneto-catalytic therapy by
eMIONs and proposed cellular pathways. b Viabilities of A549 cells receiving different concentrations of eMIONs with/without alternative magnetic field
(AMF). Data are presented as mean ± SD (n= 5 biologically independent samples). c Fluorescence image of AM/PI stained A549 cells after therapy. Scale
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Student’s t test (b, e), with P values showed in the figures.
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parameters. As shown in Fig. 3h, the O2 production of eMIONs
was 4.45 mg/mL, which was approximately eight times higher
than that of fMIONs (CFe= 5 μg/mL, CH2O2= 100 μM, pH= 6.8,
25 °C). More interestingly, the catalytic rate of eMIONs in AMF
was ~44% higher. To better understand how the AMF affected the
O2 production, we studied Michaelis–Menten steady-state
kinetics (Fig. 3i). Accordingly, eMIONs had similar initial
velocity (V0) with/without AMF as confined in varying H2O2
concentrations, but the maximum velocity (Vmax) was augmented
by ~1.26 times under a magnetic field (15 kA/m, 300 kHz, CFe=
5 μg/mL, CH2O2= 100 μM). Notably, the Michaelis constant
(Km) of eMIONs in AMF was decreased by half, which means
eMIONs exhibited better catalytic efficacy. It is speculated that
the change of the catalytic property of eMIONs was due to the
increased reaction probability on the catalytic lattice plane as well
as the rising temperature in AMF.
Magnetic and catalytic study of eMIONs in vitro. Molecular
MRI provides a promising tool to test the cell–eMION interac-
tions25. The cell-internalized eMIONs shortened the spin–spin
relaxation time and resulted in obviously decreased signal
intensities on T2-weighted images (Supplementary Fig. 7a). Next,
cytotoxicity of encABC and eMIONs were studied in a series of
cell lines by MTT assay (Supplementary Fig. 7b, c). Interestingly,
we found that the cell viabilities of all the normal cells (293T and
LO2) were >90%, which were much higher than those of the
tumor cells (below 80%, where the A549 cells were 68.7%). The
result indicated a significant difference that denotes tumor-
specific toxicity caused by the catalysis of eMIONs. We detected
the concentration of H2O2 in these cell lines with or without
eMIONs. The tumor cell lines had over two times higher levels of
H2O2 than normal cells (Supplementary Fig. 7d), and eMIONs
could catalyze ~50% of H2O2 in tumor cells. Thus, we proposed
that eMIONs could provide cancer therapy through magnetic
hyperthermia and catalytic therapy26–30 (Fig. 4a). As expected,
eMIONs without/with AMF (15 kA/m, 300 kHz, and 10 min)
killed almost 35%/65% of the treated A549 tumor cells after 24-h
incubation (Fig. 4b, c), and a similar finding was observed in LM3
tumor cells (Supplementary Fig. 8), whereas the fMIONs showed
no obvious effect (Supplementary Fig. 9). Afterward, we investi-
gated the cell-damage mechanism caused by MCT. The results
revealed that HSP 70, Bid, and cleaved caspase-3 were activated
by MHT, reflecting the onset of apoptosis (Fig. 4d, e). Moreover,
the expression of HIF-1α and VEGF was sharply declined by 52.8
and 51.1% after being incubated with eMIONs, and further
reduced by 32.8 and 45.2% with AMF, respectively. These results
showed that eMIONs could generate heat, induce apoptosis, and
synergize its catalyzation to realize MCT effects.
In vivo MCT based on eMIONs. In order to minimize the
adverse effects and maximize the therapeutic effect, MRI and
ICP-MS assay were applied to monitor the in vivo behavior of
eMIONs (CFe 2 mg/kg) in an A549 subcutaneous xenograft model
after i.v. injection (Fig. 5a–d). Both MRI and ICP-MS results
showed that eMIONs were eliminated effectively from the liver
and kidneys, but maintained at high levels in the tumor because
of the tumor EPR effect and 9 h post injection appears to be the
optimal time point for therapy intervention when the tumor
accumulation reaches the peak value (Fig. 5e and Supplementary
Fig. 10). To monitor the oxyhemoglobin saturation changes in the
tumor region, PA-US imaging was used to evaluate the catalytic
efficiency after i.v. injection of eMIONs (Fig. 5f). It was found
that the tumor O2 level of eMIONs group was about 13 times
higher than that of the PBS group (Fig. 5g).
The MCT antitumor effects were further evaluated in A549
tumor-bearing mice. As shown in Fig. 5a, the AMF (15 kA/m,
300 kHz, and 10 min) was performed at 9 h post injection, and
tumor growth rates were monitored every 2 days to assess the
therapeutic effects. A randomly chosen mouse from each group
was sacrificed to harvest tumor tissues for further immunofluor-
escence (IF) examination. The IF results demonstrated that the
expression of HIF-1α, VEGF, and CD 31 was significantly
downregulated in eMIONs group and was much lower in
eMIONs+AMF group compared with the other groups, showing
that the catalytic effect changed the tumor microenvironment to
inhibit angiogenesis (Fig. 5h, i). As expected, the A549 tumor
growth in eMIONs+AMF group was greatly inhibited, and the
tumor volume was even reduced 93% compared to that of the
PBS group. In addition, eMIONs group offered much better
inhibition (46%) than fMIONs because of their efficient catalysis
to inhibit tumor angiogenesis (Fig. 5j, k). The H&E staining
results of tumors also showed a similar trend of therapeutic effect
(Supplementary Fig. 11a). The systemic toxicity of eMIONs was
measured via hematological parameters, body weight, and H&E
analysis of major organs (Supplementary Fig. 11b–d). The
biochemical indexes of the liver and kidney function, such as
alanine transaminase (ALT), aspartate aminotransferase (AST),
lactic dehydrogenase (LDH), creatine kinase (CK), and urease
(UREA) of all groups were within normal ranges (Fig. 5l).
Furthermore, no obvious body weight changes and organ damage
were observed in any of the treated groups.
To further assess the capacity of eMIONs for deep-seated
tumor therapy, we carried out MCT on BALB/c nude mice
bearing fLuc-LM3 orthotopic HCC (Fig. 6a). As shown in Fig. 6b,
the orthotopic HCC model was detected and monitored by
bioluminescence imaging, MRI, and ultrasound imaging (US).
The changed T2 signals revealed the homogenous distribution of
eMIONs in HCC with US-mediated intratumoral injection
(Fig. 6c). After three times of treatments, quantitative biolumi-
nescence measurements of orthotopic HCC among the different
groups demonstrated a significant difference in tumor area
(Fig. 6d, e). Tumor growth rates in the eMIONs+AMF and
eMIONs groups were decreased by 68.5 and 31.8% compared to
the PBS control group, respectively. These results revealed that
AMF played a key role in locoregional HCC treatment due to its
hyperthermia and promotion for catalysis therapy. During 14 days
of therapy, the body weight of the mice showed no obvious
Fig. 5 Subcutaneous tumor model theranostics by encapsulin-produced magnetic iron oxide nanocomposites (eMIONs). a Schematic illustration of
animal therapy by eMIONs. b–emagnetic resonance imaging (MRI) images with heatmap of the tumor (b), liver (c), and kidney (d) at different time points
after injection and semiquantitative analysis (e). Data are presented as mean ± SD (n= 3 biologically independent mice). f, g PA-US imaging detected
oxyhemoglobin saturation of tumor region after injection (f) and semiquantitative analysis (g). Data are presented as mean ± SD (n= 3 biologically
independent mice). h, i Expression of HIF-1α, VEGF, and CD 31 in tumor regions were detected by immunofluorescent staining after different treatments.
One of the three repetitions with similar results is shown here. Scale bar: 20 μm. j, k Tumor growth curves (j) and representative tumors (k) showing
significantly improved antitumor efficacy of eMIONs with AMF compared with other groups. Data are presented as mean ± SD (n= 5 biologically
independent mice). l Liver and kidney function of mice were detected after treated by different means. Statistical significance was calculated with two-
tailed Student’s t test (g, j), with P values indicated in the figures.
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changes among all of the groups (Fig. 6f), indicating no severe
adverse effects from this therapy.
Next, a randomly chosen mouse from each group was
sacrificed to harvest tumor tissue and main organs for further
H&E staining to visually observe the efficiency of MCT at day 14.
As shown in Fig. 6g, the tumor from the eMIONs+AMF group
was much smaller than the other groups. The H&E staining
(Fig. 6h and Supplementary Fig. 12) showed that eMIONs
suppressed tumor invasion to a certain degree compared with the
control group, and tumor cells were killed more in the eMIONs
+AMF group, which inhibited its invasion but with no obvious
systemic toxicity. Blood from the eye socket was obtained to
measure liver function. As shown in Fig. 6i, liver function of
eMIONs+AMF group was slightly impacted compared to that in
the PBS group, and demonstrated that eMIONs are effective for
HCC therapy. Furthermore, the survival curve of these mice
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showed that the mice survival time of eMIONs+AMF group
nearly double compared to the PBS group (Fig. 6j), demonstrating
that eMIONs could be excellent MHT agents to suppress
orthotopic tumor growth under guided imaging due to its
catalysis and magnetic properties. Taken together, eMIONs could
overcome the obstacle of MHT with MRI monitoring to guide the
treatment and show safe and high therapeutic efficacy.
Discussion
Benefitting from the capacity of minimally invasive and local
hyperthermia ablation of deep-seated lesions, MHT using IONs
as heat mediators has been used in the clinic, such as anticancer
therapy31. It is strongly desirable to develop high-performance
IONs to improve MHT efficacy and the safety profile of IONs. In
this work, we have addressed the fundamental principles of
eMIONs as MHT agents and basics of magnetic hyperthermia,
including the nanoparticle size, composition, magneto-crystalline
anisotropy, and magnetization effects, on the magnetic-heat-
induction ability of eMIONs. EncapsulinABC magnetic protein
nanocages were genetically engineered to produce eMIONs with
superior magnetic responsiveness via a biosynthetic procedure.
The degree of crystallinity of eMIONs reaches up to ~100%,
possibly due to the high expression quantity of inner-function
proteins encB and encC. Interestingly, we demonstrate that, in
the structure of eMIONs, Fe3O4 has FeO subdomains, which
might form Fe2+-deficient Fe3O4 within AMF because of the
instability of FeO32. Also, we reveal that eMIONs are multi-
domains nanoparticles, which have magnetic domains and rem-
nant magnetization that could produce coercive force via hys-
teresis losses in the presence of magnetic field, and that leads to
significantly improved energy-dissipation rate to enhance the
magnetic-to-thermal conversion capacity. Thus, the SAR value of
eMIONs is as high as 2390W/g, which is over 20 times higher
than that of Feridex (FDA approved IONs)5. Taken together, it is
not surprising that eMIONs are able to cause a rapid increase in
temperature both in vitro and in vivo under AMF.
Furthermore, the mechanism reveals that eMIONs are catalase-
like nanozyme in the mild acidic environment, and the catalytic
efficiency could be significantly improved within AMF. Therefore,
eMIONs could catalyze endogenous H2O2 into O2 to regulate
TME, leading to angiogenesis inhibition with a significant
decrease in the expression of HIF-1α27–29. As a result, the
superior magnetic reactors achieved MCT to inhibit tumor
growth and extend the survival time of orthotopic HCC-bearing
mice. To the best of our knowledge, this is the first demonstration
of MCT antitumor efficacy with eMIONs that is an ideal MCT
agent suitable for the treatment of deep solid tumors.
Although many chemical synthetic XIONs (X=Mn, Co, Mg,
etc.) show excellent magnetic-to-thermal capacity, random size
distribution, and high manufacturing cost limit their clinical
translation11,33. In this work, inspired by the advantages of high
protein yield, simple procedures, and low price in Escherichia coli
(E. coli) expression system34, we obtain eMIONs with favorable
homogeneity, showing that the unique scaffold of protein nano-
cages have been used in clinical practice, Hecolin is the first
nanocage-based vaccine against hepatitis E virus, which licensed
by the State Food and Drug Administration of China35. Another
example is Aβ1-6 peptide coupled RNA bacteriophage Qβ
nanocage, which has been in Phase 2 clinical trials for Alzhei-
mer’s disease36. Therefore, the E. coli recombinant natural iron-
storage magnetic protein nanocages are suitable for a transla-
tional pipeline, although more toxicological evaluation is needed.
Overall, eMIONs have achieved tumoral precise diagnosis and
imaging-guided effective therapy in subcutaneous and deep-
orthotopic models, while continued studies to improve specificity
for MCT are being explored. For example, active targeting
ligands, including peptides and antibodies, could be introduced to
eMIONs via genetic engineering technology for better tumor
accumulation. Apart from this, other robust protein engineering
strategies, such as metal ion-assisted interface re-engineering
technology37, can be used to expand the biofunctions of eMIONs,
providing an optimal condition as a nanoreactor for catalysis and
magnetism properties. Furthermore, eMIONs have the potential
to be a favorable magnetic particle imaging (MPI) agent due to
the excellent magnetization and optimal size38,39, and the efforts
are now underway in our laboratory. Notably, eMIONs also can
be extended to coordinate with other chemotherapeutic agents
that can work in combination with MHT to achieve more com-
prehensive therapeutic results.
In summary, inspired by the natural iron-storage protein, we
have genetically recombined and biomimetically mineralized a
magneto-protein nanocage as a unique, powerful MHT agent,
which integrates potent magnetic-to-thermal conversion effi-
ciency, magnetic-enhancing catalysis, and excellent MRI ability
into a single particle to surmount the clinical challenges of MHT.
Such a simple and valuable bioinspired strategy will not only
provide new insight into MHT development but also can be
extended to therapeutics for other diseases, such as diabetes by
precise regulation of glucose metabolism via heat-mediated signal
transduction in cells40,41.
Methods
Materials. BCA protein assay kit (#23225) and Isopropylthio-β-D-
thiogalactopyranoside (IPTG, #R0392) were purchased from Thermo Fisher Sci-
entific (USA). β-actin (#ab 8226), HSP 70 (#ab 5439), Bid (#ab 10640), Cyt C (#ab
133504), VEGF (#ab 32152), and Caspase-3 (#ab 13847) antibodies were purchased
from Abcam (USA). Bax (#YM 3619) and HIF-1α (#YT 2133) antibodies were
purchased from ImmunoWay Biotechnology, Inc (USA). Calcein-AM and propi-
dium iodide assay kit (#04511) and MTT (#M2128) were obtained from Sigma-
Aldrich (USA).
Expression and purification of recombinant encapsulinABC. Gene sequence of
encA (MXAN_3556), encB (MXAN_3557), and encC (MXAN_4464) were chosen
from GenBank, and constructed into vector pRSFDuet-1 (encA) or pCDFDuet-1
(encB and encC), respectively, by Sangon Biotech (Shanghai), Co., Ltd, China. A
single colony of E. coli BL 21 (DE 3) cells, transformed with protein expression
plasmid, was transferred into 5 mL LB medium, supplemented with 100 ng/μL
antibiotic, and incubated overnight at 37 °C with 180 rpm shaking. The overnight
preculture was then inoculated into 500 mL LB medium and incubated at 37 °C
with 180 rpm shaking. Recombinant protein production was induced at OD600=
0.6 by the addition of 1 mM IPTG for another 4-h incubation. Cells were pelleted
by centrifugation at 7000 × g for 10 min at 4 °C, and resuspended in tenfold
(volume per gram of cell pellet) in lysis buffer for sonication on ice with 2-s burst of
sonication at 40% amplitude and 4-s of cooling, the total time of sonication is 7
min. Cell lysate clarified by centrifugation at 10,000 × g, 10 min, 4 °C, and then
polyethylene glycol added to the supernatant on ice and mixed for 45 min, after
which precipitated proteins were pelleted. The pellets were resuspended in PBS (pH
7.0) on ice for 1 h, and then centrifuged at 10,000 × g, 10 min, 4 °C to remove the
sediment. The supernatant was filtrated using 0.22-μm syringe filter (Millipore,
UK) for molecular sieve (AKTA Purifier, GE). The collected proteins were verified
by SDS-PAGE, dynamic light scatter (DLS), and cryo-electron microscope (Cryo-
EM), and then stored at 4 °C.
Preparation of eMIONs and fMIONs. First, a radius flask (50 mL) with a stirrer
was filled with Argon gas, then added a degassed NaCl solution (pH 8.5, 8.0 mL,
100 mM) and encABC (2 mg) with stirring of 1000 rpm and 50 °C. Next, Fe2+
(125 mM, FeSO4·6H2O) and fresh H2O2 (41.7 mM) were slowly added into the
vessel (5 μL/min) by syringe simultaneously. In total, 50 mM NaOH was titrated
into a vessel to keep pH to 8.5. For the fMIONs, ferritin (2 mg) was added into an
Argon gas-filled radius flask, followed by the addition of 8 mL degassed 100 mM
NaCl solution to the flask. Next, Fe2+ (12.5 mM, FeCl2·4H2O) and fresh H2O2
(4.17 mM) were injected into the vessel (31.3 μL/min) by syringe simultaneously. In
all, 50 mM NaOH was titrated into a vessel to keep pH to 8.5. The reacted tem-
perature was kept at 65 °C, and with 1000 rpm stirring for 1 h. After the reaction,
the solution purified via ultrafiltration (30 KDa, 2000 rpm/30 min), and then
resuspended in 2 mL PBS.
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Characterization of eMIONs and fMIONs. Then, the collected eMIONs and
fMIONs were characterized by DLS (Malvern Instruments, Malvern, UK), TEM
(TecnaiG2 Spirit, FEI), BCA kit (Thermo Fisher), Inductively Coupled Plasma
Mass Spectrometer (ICP-MS). The crystallinity and composition of samples were
measured by X-ray diffraction (XRD, Rigaku Ultima IV, Japan) and X-ray pho-
toelectron spectroscopy (XPS). Magnetic characterizations of the samples were
represented by a vibrating-sample magnetometer (VSM) option under a magnetic
field up to 20 kOe at 5 K. The T2-weighted MR imaging ability was performed with
a 9.4-T MRI scanner (Bruker, USA).
Specific absorption rate (SAR) measurement. The magnetic-to-thermal con-
version capacity of eMIONs was measured by SAR-based time-dependent calori-
metric measurements under AMF. eMIONs with a series of concentration (0.1, 0.2,
0.5 mM) were positioned at a circular copper coil (10-turn copper coil with an 8 cm
outer diameter). Magnetic field was produced by an AMF generator (SPG-10-II,
Shenzhen Double-Power Technology Co. Ltd. China) and with different powers
(10, 15, 20 KA/m, 300 kHz). The temperature changes of the samples were mea-
sured by a thermocouple thermometer (TES-1310, Taiwan). Finally, the SAR value
was calculated using the following Eq. (1)42:
SAR ¼ CP
ΔT
Δt
´
mV
mNP
; ð1Þ
where Cp is the heat capacity of the medium, ΔT/Δt is the experimentally observed
heating rate, mV is the mass of the suspension, mNP is the iron content of the
suspension.
Study of catalase-like ability of eMIONs. The oxygen generation and its gen-
erated rate in aqueous solutions were used to represent the catalase-like ability of
eMIONs. For the catalysis ability detection, the fresh H2O2 (8.8 M) was diluted to
100 mM by deoxygenated water with different pH (5.5, 6.5, and 7.4), and then 30
mL prepared H2O2 was injected in a 50 mL of closed three-neck flask with oxygen
electrode probe of portable dissolved oxygen meter (Rex, JPBJ-608, China) to
measure the concentration of oxygen in solution real time. The eMIONs and
fMIONs with different concentrations (0.1, 0.5, 1.0, 2.0, and 5 μg/mL) were injected
into the flask by a syringe. Then, the device was placed in a water bath with
different temperatures (25, 37, and 43 °C) and AMF to detect the effect of tem-
perature and magnetic field on the catalytic efficiency of eMIONs. Finally, the
Michaelis–Menten kinetic curves of eMIONs and fMIONs were gained by plotting
the respective initial velocities, and the maximal velocities were calculated by the
Lineweaver–Burk plotting with Prism 7.0.
Cellular experiments. To evaluate the magneto-catalytic therapeutic ability, A549,
LM3, U87, 4T1, HUEVC, MSC, LO2, and 293T cell lines were used as cell models
and cultured in DMEM (with 10% FBS) at 37 °C with 5% CO2. Cells (1 × 104) were
seeded on a 96-well plate overnight, then added eMIONs or fMIONs with different
concentrations (1.0, 2.5, 5.0, 10.0, 20.0 μg/mL), and closed by aseptic paraffin to
culture another 6 h. The medium was replaced with a fresh one and closed by
aseptic paraffin, and the hyperthermia groups to receive MHT (15 KA/m, 300 kHz,
10 min), then incubated for another 12 h. After that, a standard MTT assay was
utilized to evaluate the cell viabilities (n= 5).
For AM/PI staining, calcein-AM and propidium iodide solutions (4 μM) were
added into A549 cell lines (3 × 105/well, six-well plate) after different treatments,
and then incubated for 30 min, after that, washed three times with PBS carefully for
fluorescence image by inverted microscopes (Nikon DS-Ti2).
Western blotting experiments to verify the protein expression of the apoptosis
signal path, HSP 70, HIF-1α, and VEGF. A549 cell lines were seeded on a six-well
plate (3 × 105/well) to incubate overnight. Then the samples were received different
treatments as mentioned above. The cells were harvested for western blotting, and
the abundance of proteins was calculated via Image J2x (2.1.4.7, Rawak
Software, Inc).
In vivo MR imaging. Animal experiments were approved by the Animal Care and
Use Committee (CC/ACUCC) of Xiamen University. Male BALB/c nude mice
(6 weeks, ∼20 g) were obtained from Beijing Vital River Laboratory Animal
Technology Co. Ltd. For the subcutaneous xenograft tumor model, 106 A549 cells
were injected into the right flank of nude mice, and housing conditions of mice is
the specific pathogen-free (SPF) laboratory animal center, the humidity keeps at
40–60% (26–28 °C), and keeps at 10 h of light and 14 h of dark cyclic condition.
The mice were used when their tumor volumes reached ~100 mm3. The eMIONs
(CFe 2 mg/kg) were injected via tail vein, and MR imaging was executed on a 9.4-T
scanner (Bruker, USA) at the scheduled time (0, 3, 6, 12, and 24 h), respectively. T2-
weighted MR images were obtained with the following parameters: TR= 2500, TE
= 33 ms, field of view (FOV)= 4 × 4 cm, slice thickness= 1 mm, and 19 con-
tiguous slices.
In vivo magneto-catalytic therapy assisted by eMIONs. For in vivo investiga-
tions, when the tumors reach ~100 mm3, the mice were randomly divided into six
groups (n= 5). Then the mice treated with CFe 5 mg/kg of various formulations at
day 1, 4, and 7 through the tail vein. In groups only AMF, fMIONs with AMF, and
eMIONs with AMF, the tumors were received with AMF (15 KA/m, 300 kHz, 10
min) at 9 h after injection. For the orthotopic model, we established orthotopic
HCC, as described previously. Briefly, a laparotomy executed in the anesthetized
nude mouse, and then 25 μL fLuc-LM3 cells (107) were injected into the right liver
lobe. After 12 days, bioluminescence imaging by IVIS Lumia II was utilized to
screening out tumor-bearing mice, and randomly divided into three groups (n=
5). Then the mice treated with CFe 11.2 μg/per mouse by ultrasound imaging-
guided intratumor injection, and monitoring the delivery via MRI at days 1, 4, and
7. After that, in group eMIONs with AMF, the tumors were received with AMF (15
KA/m, 300 kHz) for 10 min. On day 14, we collected about 200 μL blood of the
mice from the orbit, and randomly sacrificed a mouse from each group for further
H&E staining and immunofluorescence staining.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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